Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study | Zendy

Suzanne Lentzsch | Zendy; Galina Lagos | Zendy; Raymond L. Comenzo | Zendy; Jeffrey A. Zonder | Zendy; Keren Osman | Zendy; Samuel Pan | Zendy; Divaya Bhutani | Zendy; Silva Pregja | Zendy; Vaishali Sanchorawala | Zendy; Heather Landau | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study

Author(s) -

Suzanne Lentzsch,

Galina Lagos,

Raymond L. Comenzo,

Jeffrey A. Zonder,

Keren Osman,

Samuel Pan,

Divaya Bhutani,

Silva Pregja,

Vaishali Sanchorawala,

Heather Landau

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.19.01721

Subject(s) - medicine , bendamustine , al amyloidosis , nausea , adverse effect , dexamethasone , multiple myeloma , gastroenterology , refractory (planetary science) , amyloidosis , vomiting , surgery , rituximab , lymphoma , immunology , immunoglobulin light chain , physics , antibody , astrobiology

No established treatments exist for relapsed/refractory systemic light-chain (AL) amyloidosis. Bendamustine has shown potential in the treatment of multiple myeloma. We conducted a phase II, multicenter trial to assess the efficacy and safety of bendamustine with dexamethasone (ben-dex) in patients with persistent or progressive AL amyloidosis after ≥ 1 prior therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research